
MURA
Healthcare · Biotechnology · $35.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 31, 2026 | Time not confirmed | -0.37 | 0.00 | +100.0% |
| Nov 6, 2025 | Time not confirmed | -0.30 | -0.21 | +30.0% |
| Aug 4, 2025 | Time not confirmed | -1.10 | -2.78 | -152.7% |
| May 20, 2025 | Time not confirmed | -1.98 | -1.93 | +2.5% |
| Mar 11, 2025 | Time not confirmed | -1.99 | -2.01 | -1.0% |
| Nov 13, 2024 | Time not confirmed | -1.97 | -1.87 | +5.1% |
| Aug 13, 2024 | Time not confirmed | -1.95 | -1.86 | +4.6% |
| May 14, 2024 | Before the open | -2.66 | -1.84 | +30.8% |
| Mar 26, 2024 | Before the open | -3.57 | -3.57 | +0.1% |
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and…